Founded in 2017 and headquartered in Boston, MA, Life Biosciences is pursuing therapies targeting three molecular pathways that regulate the biology of aging: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Our platform approach enables us to develop pharmaceutical treatments with the potential to prevent, treat, and/or reverse multiple aging-related diseases, each with critical unmet needs.

Aging is the biggest risk factor for almost every chronic disease. Ground-breaking research over the past decade has shown that aging is a modifiable risk factor that can be targeted therapeutically. Developing medicines that modify aging biology to prevent, delay, and/or reverse diseases of aging has the potential to transform the practice of medicine.